行情

MEIP

MEIP

MEI Pharma
NASDAQ

实时行情|Nasdaq Last Sale

1.560
+0.050
+3.31%
盘后: 1.620 +0.06 +3.85% 17:39 04/08 EDT
开盘
1.540
昨收
1.510
最高
1.640
最低
1.490
成交量
38.57万
成交额
--
52周最高
3.410
52周最低
0.7200
市值
1.65亿
市盈率(TTM)
-3.1269
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MEIP价格均价为8.21,最高价位11.00,最低价为5.50。

EPS

MEIP 新闻

更多
  • MEI Pharma to Present at the 19th Annual Needham Virtual Healthcare Conference
  • PR Newswire · 16小时前
  • MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma
  • PR Newswire · 03/31 13:00
  • MEI Pharma's ME-401 Fast Track'd for follicular lymphoma; shares up 4% premarket
  • Seeking Alpha - Article · 03/31 12:54
  • MEI Pharma Announces Fast Track Designation Granted By FDA For ME-401 For Treatment Of Adult Patients With Relapsed Or Refractory Follicular Lymphoma
  • Benzinga · 03/31 12:21

所属板块

生物技术和医学研究
+3.06%
制药与医学研究
+2.82%

热门股票

代码
价格
涨跌幅

MEIP 简况

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
展开

微牛提供MEI Pharma Inc(NASDAQ-MEIP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MEIP股票新闻,以帮助您做出投资决策。